| |
Designed for managing oral mucositis
 GELCLAIR® was
cleared by the FDA
in 2001 and is specifically designed and
approved for management and relief of pain
in oral mucositis. It contains key
ingredients that protect, hydrate and soothe
the mouth and has a mild flavor.
GELCLAIR® is designed to be
non-numbing, non-stinging and
non-drying.10,11
GELCLAIR® has been shown to
reduce the pain of oral mucositis, allowing
more normal eating and drinking.
Short-term results
In an open-label study* 30 patients
experienced a 92% reduction in mean overall
oral pain associated with lesions of the
mouth and oropharynx 5 to 7 hours after
treatment.11,12
Medium-term results
In the same open-label study* 87% of
patients reported reduced pain associated
with swallowing foods, liquids, and saliva
after 7 days of use.11,12
Safety profile after several years of use
At the time of writing this information, no
side effects have been reported in clinical
trials with the use of GELCLAIR®. Postmarketing reports have included
infrequent complaints of burning sensation
in the mouth.
* Open-label study of 30 patients with
painful lesions of the mouth and oropharynx
associated with chemotherapy, radiation,
mucositis, HIV disease, severe diffuse
apthous ulcers, or oral surgery. Pain was
scored on a Visual Numerical Scale ranging
from 0 (no pain) to 10 (worst pain), with
scores recorded at baseline and at 5 to 7
hours after treatment. Gelclair was
administered three times a day.11 |
|
 |
